Key result
Digoxin for ambulatory HF shows ~12% discontinuation with rare supratherapeutic toxicity.
Why the study?
Digoxin use in HF has declined due to safety concerns and limited recent evidence, but the DIGIT-HF trial renewed interest in its role for persistent symptoms or tachycardia, creating a need for updated real-world data on its prescribing patterns and safety.
What are the real-world prescribing patterns, indications, monitoring practices, and safety outcomes of digoxin in ambulatory patients with heart failure?
Cohort (n=59)
What are the real-world prescribing patterns, indications, monitoring practices, and safety outcomes of digoxin in ambulatory patients with heart failure?
In contemporary ambulatory heart failure practice, digoxin is predominantly used for atrial arrhythmia rate control rather than sinus rhythm HFrEF management and demonstrates low rates of toxicity when monitored.
Answers are grounded in this paper and cite their sources.
Supports predominant atrial arrhythmia use with low toxicity in ambulatory HF; leaves open efficacy in sinus-rhythm HFrEF.
Introduction Digoxin use in HF has declined due to safety concerns and limited recent evidence, but the DIGIT-HF trial renewed interest in its role, particularly for patients with persistent symptoms or tachycardia. Updated real-world data on its use and safety are therefore needed. Purpose To characterize real-world prescribing patterns, indications, monitoring, and safety outcomes of digoxin in patients with HF. Methods We performed a retrospective observational study of ambulatory HF patients treated with digoxin, collecting demographic, clinical, echocardiographic, therapeutic, and follow-up outcome data, including indications for initiation and serum digoxin levels. Results A total of 59 patients were included, with a mean age of 69.8 ± 11.6 years, BMI 28.3 ± 8.46 kg/m², and advanced systolic dysfunction (mean LVEF 32.6%). Baseline heart rate averaged 75.7 ± 15.4 bpm, and mean systolic/diastolic blood pressures were 115.9 ± 20.3 and 69.1 ± 12.4 mmHg. Biomarker and renal profiles reflected significant disease burden, with a median NT-proBNP of 2134 pg/mL (IQR 1017–3595), mean creatinine 1.20 ± 0.36 mg/dL, and estimated GFR 57.6 ± 21.0 mL/min/1.73m²; chronic kidney disease was present in 30.5%. Atrial arrhythmias were highly prevalent, with atrial fibrillation in 62.7% of patients, whereas sinus rhythm was uncommon (1.7%). Non-ischemic cardiomyopathy predominated (72.4%), and most patients met criteria for HFrEF (72.9%). Digoxin was mainly prescribed for atrial arrhythmia–related rate control, accounting for almost 90% of indications: 58.6% (n=34) for presumed tachycardiomyopathy with rapid ventricular response and 31.0% (n=18) for rate control irrespective of LVEF. Only 10.3% (n=6) received digoxin primarily for HFrEF management. Serum digoxin was measured in 34 patients (52 assays), with only one supratherapeutic level (>2 ng/mL), indicating good safety. Digoxin was discontinued in 7 patients (11.9%), mainly due to lack of perceived benefit (57.1%), with isolated cases related to renal function decline, toxic levels or iatrogenic concerns (each 14.3%). Outcomes after withdrawal were favorable, with only one HF hospitalization recorded. Conclusions In this real-world cohort, digoxin was used mainly for atrial arrhythmia rate control and showed a favorable safety profile, with rare toxicity and few adverse events even after discontinuation. These findings support its ongoing role as a targeted rate-control option in selected HF patients.
No takes yet. Share an insight, caveat, or question.
Malveiro et al. (2026) conducted a cohort in Heart failure (n=59). Digoxin was evaluated on Real-world prescribing patterns, indications, monitoring, and safety outcomes (supratherapeutic levels and discontinuation). Digoxin was prescribed mainly for atrial arrhythmia rate control in ambulatory HF patients and discontinued in 11.9%, with only 1 supratherapeutic level among 34 monitored patients.
Synapse has enriched 10 related papers. Consider them for comparative context: